169 related articles for article (PubMed ID: 19780253)
41. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
Baskaran ND; Gan GG; Adeeba K
Ann Hematol; 2008 Jul; 87(7):563-9. PubMed ID: 18437382
[TBL] [Abstract][Full Text] [Related]
42. Infections of febrile neutropenic patients in malignant hematological diseases (second study period).
Rókusz L; László L
Mil Med; 2005 Aug; 170(8):653-7. PubMed ID: 16173203
[TBL] [Abstract][Full Text] [Related]
43. Impact of Fluoroquinolone Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients.
Caro J; Madero-Marroquin R; Zubizarreta N; Moshier E; Tremblay D; Coltoff A; Lancman G; Fuller R; Rana M; Mascarenhas J; Jacobs SE
Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):903-911. PubMed ID: 36109322
[TBL] [Abstract][Full Text] [Related]
44. Current treatments for infection in neutropenic patients with hematologic malignancy.
Greene JN; Linch DC; Miller CB
Oncology (Williston Park); 2000 Aug; 14(8 Suppl 6):31-4. PubMed ID: 10989822
[TBL] [Abstract][Full Text] [Related]
45. [Cefepime-amikacin combination in febrile neutropenic children with malignant hemopathy or tumor].
Marie-Cardine A; Schneider P; Blot N; Tron P; Vannier JP
Arch Pediatr; 2003 Apr; 10(4):307-12. PubMed ID: 12818750
[TBL] [Abstract][Full Text] [Related]
46. Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients.
Cruciani M; Malena M; Bosco O; Nardi S; Serpelloni G; Mengoli C
J Clin Oncol; 2003 Nov; 21(22):4127-37. PubMed ID: 14615441
[TBL] [Abstract][Full Text] [Related]
47. [Antimicrobial prophylaxis and therapy in neutropenia].
Link H
Mycoses; 2003; 46 Suppl 2():21-32. PubMed ID: 15055140
[TBL] [Abstract][Full Text] [Related]
48. Safe fluoroquinolones prophylaxis in blood cancer patients with chemotherapy-induced neutropenia and Glucose-6-Phosphate-Dehydrogenase deficiency.
Sanna M; Caocci G; Orrù F; Ledda A; Vacca A; Piras E; Fozza C; Deias P; Tidore G; Dore F; La Nasa G
J Clin Pharm Ther; 2017 Dec; 42(6):733-737. PubMed ID: 28597476
[TBL] [Abstract][Full Text] [Related]
49. Moxifloxacin is more effective than tosufloxacin in reducing chemotherapy-induced febrile neutropenia in patients with hematological malignancies.
Shinohara A; Yoshiki Y; Masamoto Y; Hangaishi A; Nannya Y; Kurokawa M
Leuk Lymphoma; 2013 Apr; 54(4):794-8. PubMed ID: 22978686
[TBL] [Abstract][Full Text] [Related]
50. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Fever and neutropenia: the early years.
Bodey GP
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i3-13. PubMed ID: 19372179
[TBL] [Abstract][Full Text] [Related]
51. [Bacteremia due to Capnocytophaga species during chemotherapy-induced neutropenia in patients with hematological malignancies].
Murakami K; Mori T; Kato J; Shimizu T; Kohashi S; Sakurai M; Sugita K; Hasegawa N; Murata M; Okamoto S
Rinsho Ketsueki; 2017; 58(3):210-215. PubMed ID: 28381687
[TBL] [Abstract][Full Text] [Related]
52. [Prophylactic antibiotic treatment of neutropenic patients].
Telekes A; Hegedüs M
Orv Hetil; 2004 Jul; 145(28):1451-7. PubMed ID: 15366711
[TBL] [Abstract][Full Text] [Related]
53. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why empirical therapy?
Klastersky J
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i14-5. PubMed ID: 19372173
[TBL] [Abstract][Full Text] [Related]
54. Antifungal prophylaxis in neutropenic patients with hematologic malignancies: is there a real benefit?
Böhme A; Karthaus M; Hoelzer D
Chemotherapy; 1999; 45(3):224-32. PubMed ID: 10224346
[TBL] [Abstract][Full Text] [Related]
55. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis.
Gafter-Gvili A; Paul M; Fraser A; Leibovici L
J Antimicrob Chemother; 2007 Jan; 59(1):5-22. PubMed ID: 17077101
[TBL] [Abstract][Full Text] [Related]
56. Emerging bacterial resistance patterns in febrile neutropenic patients: experience at a tertiary care hospital in Pakistan.
Khan MA; Siddiqui BK; Shamim A; Yosuf MA; Ahmed U; Zakiullah N; Burney IA
J Pak Med Assoc; 2004 Jul; 54(7):357-60. PubMed ID: 15449917
[TBL] [Abstract][Full Text] [Related]
57. Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia.
Verlinden A; Jansens H; Goossens H; van de Velde AL; Schroyens WA; Berneman ZN; Gadisseur AP
Eur J Haematol; 2014 Oct; 93(4):302-8. PubMed ID: 24750350
[TBL] [Abstract][Full Text] [Related]
58. A review of chemoprophylaxis and therapy of bacterial infections in neutropenic patients.
Klastersky J
Diagn Microbiol Infect Dis; 1989; 12(4 Suppl):201S-207S. PubMed ID: 2686921
[TBL] [Abstract][Full Text] [Related]
59. Antibacterial prophylaxis.
Cruciani M
Int J Antimicrob Agents; 2000 Oct; 16(2):123-5. PubMed ID: 11053792
[TBL] [Abstract][Full Text] [Related]
60. Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT).
Gudiol C; Nicolae S; Royo-Cebrecos C; Aguilar-Guisado M; Montero I; Martín-Gandul C; Perayre M; Berbel D; Encuentra M; Arnan M; Cisneros-Herreros JM; Carratalà J
Trials; 2018 May; 19(1):264. PubMed ID: 29720244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
